Drugmakers Wrestle With FDA Oversight of Rare Disease Treatments

Drug companies that specialize in care for rare diseases are growing frustrated with the FDA, despite agency leadership’s proclaimed agenda to accelerate approvals and heighten flexibility for promising new treatments.